INDIANAPOLIS, June 17, 2011 /PRNewswire/ -- The St. Francis Heart Center today (June 17, 2011) announced that it has performed the first post-FDA approval surgery in the United States using a new device for treating tricuspid valve disease.
Called the Contour 3D™ Annuloplasty Ring, the device, which is manufactured by Medtronic, is designed to restore normal valve function by remodeling the natural valve's shape and size.
The procedure was performed by Marc Gerdisch, M.D., chief of cardiothoracic surgery at Franciscan St. Francis Health and surgical director of the St. Francis Heart Valve Center. Gerdisch, a partner with Cardiac Surgery Associates, provided input during the development of the new ring.
"Our team is focused on reestablishing normal heart physiology to achieve optimal performance," said Gerdisch. "We want the best possible outcome for every single patient, and this device is part of an approach that is based on restoring dynamic anatomy that has been altered by disease."
Tricuspid valve disease is a condition in which the valve between the two right heart chambers (right ventricle and right atrium) does not function properly. Tricuspid valve disease often occurs with other heart valve problems as was the case with the first patient to receive the Contour 3D Ring.
The case involved a 74-year-old woman with congestive heart failure dating back more than a decade. The woman suffered from multiple debilitating heart issues, and because the surgery involved several of her heart's components, having an annuloplasty ring similar to the natural valve's shape was key to an overall successful procedure.
She is now recovering and doing very well, with echocardiography showing positive results,